FULC — Fulcrum Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Fulcrum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 218 | 203 | 236 | 241 | 352 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.11 | 1.08 | 2.25 | 3.34 | 1.07 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 226 | 208 | 242 | 250 | 357 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7.37 | 16 | 12.4 | 9.58 | 7.07 |
| Other Long Term Assets | |||||
| Total Assets | 235 | 227 | 258 | 261 | 366 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19.2 | 16.7 | 13.7 | 11 | 13 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 23.5 | 27.7 | 22.5 | 17.7 | 17.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 212 | 199 | 235 | 243 | 349 |
| Total Liabilities & Shareholders' Equity | 235 | 227 | 258 | 261 | 366 |
| Total Common Shares Outstanding |